Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 38 results for "frrb"

Initiated probe into Lilliput audit fraud allegations: K Raghu...

The high-profile case has been referred to the ICAI's FRRB or Financial Reporting Review Board and adds that more clarity is required on fraud reporting by auditors to the government, says K Raghu. Bain Capital's move to sue EY in a US court over a $60 ... Economic Times, 1 month ago

SEBI unveils norms for public holding, OFS, ESOP and research analysts

SEBI's Board announced new norms for public shareholding for all listed companies including PSUs, ESOP scheme, offer for sale -OFS mechanism as well as research analysts Market regulator Securities and Exchange Board of India (SEBI) on Thursday ...
 Money Life1 month ago

Cellectis and Accelera (Nerviano Medical Sciences Group) Sign an Agreement to Complete Preclinical Studies of Cellectis' Lead Product Candidate UCART19

Cellectis (Paris:ALCLS), a leader of allogeneic CAR T-cell therapies, and Accelera, the preclinical CRO (Contract Research Organisation) within the Nerviano Medical Sciences Group, recently signed an agreement to complete the preclinical studies of ...
 Fierce CRO1 month ago Cellectis et Accelera (Groupe Nerviano Medical Sciences) signent un accord pour réaliser les études précliniques de UCART19, le produit phare de Cellectis  Business Wire1 month ago
[x]  
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less